A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome
Abstract Background The optimal treatment strategy for patients with treatment‐resistant schizophrenia (TRS) associated with 22q11.2 deletion syndrome (DS) remains a subject of debate. Case Presentation We present the case of a 40‐year‐old female patient diagnosed with TRS and 22q11.2DS who was effe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12333 |
| _version_ | 1797802353561174016 |
|---|---|
| author | Arisa Tsurue Hideki Funahashi Keiichi Tsurue Masahiko Kawano Yasushi Ishida Yoji Hirano |
| author_facet | Arisa Tsurue Hideki Funahashi Keiichi Tsurue Masahiko Kawano Yasushi Ishida Yoji Hirano |
| author_sort | Arisa Tsurue |
| collection | DOAJ |
| description | Abstract Background The optimal treatment strategy for patients with treatment‐resistant schizophrenia (TRS) associated with 22q11.2 deletion syndrome (DS) remains a subject of debate. Case Presentation We present the case of a 40‐year‐old female patient diagnosed with TRS and 22q11.2DS who was effectively treated with clozapine. She was diagnosed with schizophrenia and mild intellectual disability during her adolescence; despite being hospitalized for a period of 10 years beginning in her 30s, she continued to exhibit symptoms of impulsivity, and explosive behavior, requiring periods of isolation. We ultimately decided to switch her medication to clozapine, which was administered with caution and gradually titrated upward, with no discernable adverse effects, resulting in a marked improvement in her symptoms and obviated the need for isolation. Subsequently, the patient's history of congenital heart disease and facial abnormalities prompted initial suspicions of a 22q11.2DS diagnosis, which was subsequently confirmed through genetic testing. Conclusion Clozapine may serve as an efficacious pharmacological intervention for TRS patients with 22q11.2DS, including those of Asian descent. |
| first_indexed | 2024-03-13T05:05:28Z |
| format | Article |
| id | doaj.art-0c5a0ed2071f439d9386288cde9152a1 |
| institution | Directory Open Access Journal |
| issn | 2574-173X |
| language | English |
| last_indexed | 2024-03-13T05:05:28Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj.art-0c5a0ed2071f439d9386288cde9152a12023-06-16T15:12:03ZengWileyNeuropsychopharmacology Reports2574-173X2023-06-0143227227610.1002/npr2.12333A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndromeArisa Tsurue0Hideki Funahashi1Keiichi Tsurue2Masahiko Kawano3Yasushi Ishida4Yoji Hirano5Miyakonojo Shinsei Hospital Miyakonojo JapanDepartment of Psychiatry, Faculty of Medicine University of Miyazaki Miyazaki JapanMiyakonojo Shinsei Hospital Miyakonojo JapanMiyakonojo Shinsei Hospital Miyakonojo JapanDepartment of Psychiatry, Faculty of Medicine University of Miyazaki Miyazaki JapanDepartment of Psychiatry, Faculty of Medicine University of Miyazaki Miyazaki JapanAbstract Background The optimal treatment strategy for patients with treatment‐resistant schizophrenia (TRS) associated with 22q11.2 deletion syndrome (DS) remains a subject of debate. Case Presentation We present the case of a 40‐year‐old female patient diagnosed with TRS and 22q11.2DS who was effectively treated with clozapine. She was diagnosed with schizophrenia and mild intellectual disability during her adolescence; despite being hospitalized for a period of 10 years beginning in her 30s, she continued to exhibit symptoms of impulsivity, and explosive behavior, requiring periods of isolation. We ultimately decided to switch her medication to clozapine, which was administered with caution and gradually titrated upward, with no discernable adverse effects, resulting in a marked improvement in her symptoms and obviated the need for isolation. Subsequently, the patient's history of congenital heart disease and facial abnormalities prompted initial suspicions of a 22q11.2DS diagnosis, which was subsequently confirmed through genetic testing. Conclusion Clozapine may serve as an efficacious pharmacological intervention for TRS patients with 22q11.2DS, including those of Asian descent.https://doi.org/10.1002/npr2.1233322q11.2 deletion syndromeAsianclozapinetreatment‐resistant schizophrenia |
| spellingShingle | Arisa Tsurue Hideki Funahashi Keiichi Tsurue Masahiko Kawano Yasushi Ishida Yoji Hirano A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome Neuropsychopharmacology Reports 22q11.2 deletion syndrome Asian clozapine treatment‐resistant schizophrenia |
| title | A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome |
| title_full | A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome |
| title_fullStr | A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome |
| title_full_unstemmed | A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome |
| title_short | A case study of the utilization of clozapine treatment for treatment‐resistant schizophrenia associated with 22q11.2 deletion syndrome |
| title_sort | case study of the utilization of clozapine treatment for treatment resistant schizophrenia associated with 22q11 2 deletion syndrome |
| topic | 22q11.2 deletion syndrome Asian clozapine treatment‐resistant schizophrenia |
| url | https://doi.org/10.1002/npr2.12333 |
| work_keys_str_mv | AT arisatsurue acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT hidekifunahashi acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT keiichitsurue acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT masahikokawano acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT yasushiishida acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT yojihirano acasestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT arisatsurue casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT hidekifunahashi casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT keiichitsurue casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT masahikokawano casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT yasushiishida casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome AT yojihirano casestudyoftheutilizationofclozapinetreatmentfortreatmentresistantschizophreniaassociatedwith22q112deletionsyndrome |